“Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)” (2019) SKIN The Journal of Cutaneous Medicine, 3(2), p. 175. doi:10.25251/skin.3.2.15.